NL1025070A1 - Doseringsvormen omvattende een CETP-remmer en een HMG-CoA-reductaseremmer. - Google Patents

Doseringsvormen omvattende een CETP-remmer en een HMG-CoA-reductaseremmer.

Info

Publication number
NL1025070A1
NL1025070A1 NL1025070A NL1025070A NL1025070A1 NL 1025070 A1 NL1025070 A1 NL 1025070A1 NL 1025070 A NL1025070 A NL 1025070A NL 1025070 A NL1025070 A NL 1025070A NL 1025070 A1 NL1025070 A1 NL 1025070A1
Authority
NL
Netherlands
Prior art keywords
inhibitor
hmg
dosage forms
coa reductase
cetp
Prior art date
Application number
NL1025070A
Other languages
English (en)
Other versions
NL1025070C (nl
Inventor
Dwayne Thomas Friesen
Douglas Alan Lorenz
David Keith Lyon
Bruno Caspar Hancock
Timothy Joseph Mcdermott
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL1025070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NL1025070A1 publication Critical patent/NL1025070A1/nl
Application granted granted Critical
Publication of NL1025070C publication Critical patent/NL1025070C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL1025070A 2002-12-20 2003-12-18 Doseringsvormen omvattende een cetp-remmer en een hmg-coa-reductaseremmer. NL1025070C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43534502P 2002-12-20 2002-12-20
US43534502 2002-12-20

Publications (2)

Publication Number Publication Date
NL1025070A1 true NL1025070A1 (nl) 2004-06-22
NL1025070C NL1025070C (nl) 2010-04-06

Family

ID=32682223

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1025070A NL1025070C (nl) 2002-12-20 2003-12-18 Doseringsvormen omvattende een cetp-remmer en een hmg-coa-reductaseremmer.

Country Status (24)

Country Link
US (1) US7897175B2 (nl)
EP (1) EP1581210B1 (nl)
JP (1) JP2006512359A (nl)
KR (1) KR20050088190A (nl)
CN (1) CN1728995A (nl)
AR (1) AR042534A1 (nl)
AT (1) ATE389396T1 (nl)
AU (1) AU2003286372A1 (nl)
BR (1) BR0317593A (nl)
CA (1) CA2509688A1 (nl)
CO (1) CO5590898A2 (nl)
DE (1) DE60319877T2 (nl)
ES (1) ES2300628T3 (nl)
GT (1) GT200300295A (nl)
IL (1) IL169090A0 (nl)
NL (1) NL1025070C (nl)
NO (1) NO20052779L (nl)
PE (1) PE20040970A1 (nl)
PL (1) PL377606A1 (nl)
RU (1) RU2005119176A (nl)
TW (1) TW200420301A (nl)
UY (1) UY28134A1 (nl)
WO (1) WO2004056359A1 (nl)
ZA (1) ZA200504123B (nl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
SK15172003A3 (en) * 2001-06-21 2004-11-03 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1401399A2 (en) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006129167A1 (en) * 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
DK1912626T3 (en) 2005-08-08 2016-08-01 Abbvie Deutschland Dosage forms with improved bioavailability
CA2618255C (en) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
KR100791256B1 (ko) * 2006-03-17 2008-01-03 주식회사 대웅제약 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
AU2007300071A1 (en) * 2006-09-27 2008-04-03 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
UA110117C2 (uk) * 2010-11-04 2015-11-25 Ф. Хоффманн-Ля Рош Аг Композиція, що містить s-[2-([[1-(2-етилбутил)-циклогексил]-карбоніл]аміно)феніл]2-метилпропантіоат і кроскармелозу натрію
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
JP6956005B2 (ja) * 2014-08-28 2021-10-27 デジマ・ファルマ・ベー・フェー コレステリルエステル転送タンパク質阻害剤及びＨＭＧ ＣｏＡ還元酵素阻害剤を含む医薬組成物及び治療併用剤
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
EP0680320B1 (en) 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
PT828495E (pt) * 1995-06-01 2003-01-31 Searle & Co Dispersoes solidas estabilizadas de misoprostol
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
WO1998053802A1 (en) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
WO2000038722A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
WO2001093860A1 (en) * 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2419406A1 (en) * 2000-08-15 2002-02-21 Pfizer Products Inc. Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels
US20020077348A1 (en) 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
US20040235935A1 (en) * 2001-06-12 2004-11-25 Francis Vanderbist Oral pharmaceutical composition containing a statin derivative
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
BR0317593A (pt) 2005-11-22
EP1581210A1 (en) 2005-10-05
NO20052779D0 (no) 2005-06-08
JP2006512359A (ja) 2006-04-13
ATE389396T1 (de) 2008-04-15
WO2004056359A1 (en) 2004-07-08
CA2509688A1 (en) 2004-07-08
KR20050088190A (ko) 2005-09-02
PL377606A1 (pl) 2006-02-06
US20040197398A1 (en) 2004-10-07
GT200300295A (es) 2004-08-18
DE60319877D1 (de) 2008-04-30
UY28134A1 (es) 2004-07-30
TW200420301A (en) 2004-10-16
AR042534A1 (es) 2005-06-22
ZA200504123B (en) 2006-02-22
US7897175B2 (en) 2011-03-01
NL1025070C (nl) 2010-04-06
ES2300628T3 (es) 2008-06-16
PE20040970A1 (es) 2004-12-14
CN1728995A (zh) 2006-02-01
NO20052779L (no) 2005-08-25
AU2003286372A1 (en) 2004-07-14
IL169090A0 (en) 2007-07-04
RU2005119176A (ru) 2006-01-20
CO5590898A2 (es) 2005-12-30
DE60319877T2 (de) 2009-04-30
EP1581210B1 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
NO20052779D0 (no) Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
ZA200210103B (en) HMG-CoA reductase inhibitors and method.
NO20026011D0 (no) HMG-CoA-reduktase-inhibitorer og fremgangsmåte
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
NO20052991D0 (no) Kinazolinforbindelser.
BR0208650B1 (pt) gaxeta metálica.
AP2005003251A0 (en) New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
EP1684754A4 (en) HMG COA REDUCTASE INHIBITORS AND METHOD
DE50310866D1 (de) Flanschverbindung
ITAR20020029A1 (it) Rivelatore di metalli e procedimento di verifica per il medesimo
NO20040352L (no) Forfalskningssikker metallfolie
DE50305140D1 (de) Zerstäubungsanordnung
DE50313548D1 (de) Zerstäubungsanordnung
DE60329649D1 (de) Reibschweissen
NO20034310D0 (no) Forfalskningsdetektor
NL1022900A1 (nl) Meerlaagse spiegel voor een luminescerende inrichting en werkwijze voor de vervaardiging daarvan.
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
ES1051272Y (es) Peonza multiplicable.
ITVA20020070A1 (it) Composizioni farmaceutico-dietetiche comprendenti inibitori della hmg-coa reduttasi e/o polielettroliti.
BR0202689B1 (pt) produto de aço revestido.
ES1052052Y (es) Brida.
ES1052291Y (es) Pieza para acera modular y acera modular que la incorpora.
ES1051981Y (es) Un nebulizador.
NL1022890A1 (nl) Ionisatieinrichting.

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20100204

V1 Lapsed because of non-payment of the annual fee

Effective date: 20110701